Semaglutide

Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management, developed by Novo Nordisk in 2012.Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

Read more in the app

The Lancet: Study confirms cardiovascular benefits of semaglutide beyond weight loss - EurekAlert!

Liraglutide vs semaglutide vs dulaglutide in veterans with type 2 diabetes - EurekAlert!

Nearly 20% Weight Loss Achieved With Higher Dose of Semaglutide, Study Finds

Semaglutide may silence the food noise in your head

Taking semaglutide turns down food noise, research suggests - EurekAlert!

The Lancet Diabetes & Endocrinology: Higher doses of semaglutide can safely enhance weight loss and improve health for adults living with obesity, two new clinical trials confirm - EurekAlert!

Semaglutide reduces cocaine use in rats - EurekAlert!

Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction - EurekAlert!

Ocular adverse events with semaglutide - EurekAlert!

Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes - EurekAlert!

Changes in cardiovascular risk factors and health care expenditures among patients prescribed semaglutide - EurekAlert!

Semaglutide Demonstrates Impressive Heart Benefits – Even Before You Lose Weight

Tirzepatide vs. Semaglutide: New Research Reveals Surprising Metabolic Differences

Reversing Liver Disease? Scientists Discover New Health Benefit of Semaglutide

Study reveals distinct mechanisms of action of tirzepatide and semaglutide - EurekAlert!

Semaglutide may provide early protection against heart disease in high-risk patients—even before clinically meaningful weight loss and prior to the full target dose - EurekAlert!

First head-to-head study in people living with obesity shows tirzepatide results in around 50% more weight loss than semaglutide - EurekAlert!

Patients of an online obesity clinic achieved the same weight loss as those in clinical trials of semaglutide – but with much lower doses of the drug - EurekAlert!

Landmark Study Finds Semaglutide Effectively Treats Serious Liver Disease

Semaglutide treats liver disease in two thirds of patients